TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Alterity Therapeutics ( (AU:ATH) ) has provided an update.
Alterity Therapeutics announced the results of its 2025 Annual General Meeting, highlighting the approval of resolutions by shareholders. The company continues to make strides in its clinical trials, particularly with ATH434, which has shown positive results in treating Multiple System Atrophy, potentially enhancing its market position and impact on stakeholders.
More about Alterity Therapeutics
Alterity Therapeutics is a clinical stage biotechnology company focused on developing therapies for neurodegenerative diseases, particularly Parkinson’s disease and related disorders. The company has shown efficacy in its lead asset, ATH434, through clinical trials for Multiple System Atrophy, and is engaged in drug discovery for neurological diseases.
Average Trading Volume: 14,942,225
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$97.88M
For an in-depth examination of ATH stock, go to TipRanks’ Overview page.